Key Transaction Details

  • Issue of 3,38,030 convertible warrants of face value ₹10 each to promoters
  • Warrants convertible into 3,38,030 equity shares of ₹10 each
  • Issue price: Not less than ₹1,183.32 per warrant
  • Regulatory reference: SEBI LODR Regulation 28(1)

Approval Timeline

  • Board of Directors approval: May 15, 2026 (Letter no. RHUSE/009/2026-27)
  • Shareholders approval: June 12, 2026 (Letter no. RHL/SE/027/2026-27)
  • BSE in-principle approval: July 23, 2026 (Letter no. LOD/PREF/SS/FIP/542/2026-27)
  • NSE in-principle approval: July 23, 2026

Compliance Requirements

The approval is subject to strict compliance with:

  • Companies Act, 2013
  • Securities Contracts (Regulation) Act, 1956
  • SEBI Act, 1992
  • Depositories Act, 1996
  • SEBI ICDR Regulations, 2018 (Chapter V)
  • SEBI LODR Regulations, 2015
  • Existing listing agreements

Specific Conditions Mandated by Exchanges

  • Company must strengthen internal controls to monitor trades by proposed allottees
  • Must obtain undertaking from allottees confirming they will not:
  • Conduct intra-day trading in company scrip
  • Sell any shares of the company until allotment date
  • Responsibility solely on issuer company to verify compliance with Regulation 167(6) of SEBI ICDR regulations
  • Any non-compliance may impact listing of such shares

Post-Allotment Requirements

  • Must make listing application within 20 days from allotment date (per SEBI circular SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023)
  • Must pay applicable fees
  • Must comply with post-issue formalities
  • Automatic release of excess lock-in period of pre-preferential holding by depositories without requiring NOC from exchange

Reservations and Limitations

  • In-principle approval does not constitute final listing approval
  • Exchange reserves right to withdraw approval if information is found incomplete/incorrect/misleading/false
  • Approval does not cover compliance with other Acts/Regulations/rules/byelaws
  • Company must separately obtain approvals from other departments if required

Financial Impact

Financial impact not quantified in the disclosure. The transaction involves potential equity dilution through conversion of 3,38,030 warrants into equity shares.